Tags · Access
EMA
European Medicines Agency positions and product information.
Related in this group: insurance · prior authorisation · appeals · formulary · cost per milligram · compounding · shortage · NHS · FDA · MHRA · personal import · telehealth
39 topics · page 1 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Language barriers in accessing a prescription abroad
Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this…
|
2 | 22k | 1h | |
|
Prescription portability between countries
Prescription portability between countries — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
|
+104 | 114 | 6.1k | 3h |
|
German, French and Dutch differences, compared
German, French and Dutch differences, compared — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
|
2 | 12k | 10h | |
|
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…
|
+8 | 12 | 15k | 17h |
|
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
2 | 182 | 21h | |
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+37 | 42 | 2.1k | 1d |
|
What changed in 2026, by region — does this still hold?
What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…
|
+20 | 25 | 50k | 1d |
|
[2026 update] Travelling with an injectable: documentation and practicalities
Travelling with an injectable: documentation and practicalities Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in…
|
+107 | 111 | 12k | 1d |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
+87 | 94 | 1.1k | 21d |
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. I would like to talk about documentation quality as a…
|
2 | 1.8k | 2mo | |
|
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
|
+124 | 132 | 9.2k | 2mo |
|
EU-wide position versus national implementation — what changed since
EU-wide position versus national implementation — what changed since Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included,…
|
+22 | 26 | 58k | 2mo |
|
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+7 | 11 | 39k | 3mo |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…
|
+72 | 78 | 23k | 3mo |
|
Reading a regulatory notice rather than an article about it
Posting this under the heading it deserves: Reading a regulatory notice rather than an article about it Everything below is what sits behind that. Structured report rather than an opinion, following the…
|
2 | 2.9k | 5mo | |
|
Revisiting: Language barriers in accessing a prescription abroad
Posting this under the heading it deserves: Revisiting: Language barriers in accessing a prescription abroad Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+131 | 148 | 28k | 5mo |
|
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…
|
+100 | 110 | 37k | 5mo |
|
What a regulator's shortage notice actually authorises — what changed since
The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. A logistics question, since the…
|
+22 | 26 | 53k | 7mo |
|
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of July 2026, in…
|
+5 | 9 | 3.2k | 7mo |
|
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer.…
|
+45 | 49 | 15k | 8mo |
|
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+72 | 81 | 6.9k | 8mo |
|
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
|
+70 | 74 | 7k | 8mo |
|
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
|
+90 | 99 | 32k | 9mo |
|
About the European Union category
EMA positions, national differences within the EU, and cross-border purchase rules. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+1 | 5 | 18k | 10mo |
|
Enforcement priorities versus written rules — does this still hold?
Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…
|
+36 | 40 | 37k | 11mo |
|
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…
|
+22 | 29 | 356 | 11mo |
|
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
|
+6 | 10 | 41k | 11mo |
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+12 | 16 | 2.8k | 11mo |
|
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
|
+76 | 82 | 52k | 11mo |
|
Reading a regulatory notice rather than an article about it — what changed since
Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…
|
+28 | 32 | 640 | 13mo |